Reduction of the share capital and holding of own shares (22 June
2009)
At Novo Nordisk's ordinary general meeting on 18 March 2009, it was
decided to reduce the company's B share capital from DKK 526,512,800
to DKK 512,512,800 by cancellation of part of the company's portfolio
of own B shares at a nominal value of DKK 14,000,000 divided into
14,000,000 B shares of DKK 1 each.
Today, Novo Nordisk has registered the final implementation of the
reduction of the share capital with the Danish Commerce and Companies
Agency and cancelled nominally DKK 14,000,000 B shares. After the
reduction of the share capital, the company's share capital is
nominally DKK 620,000,000, which is divided into an A share capital
of nominally DKK 107,487,200 and a B share capital of nominally DKK
512,512,800.
Holding of own shares
In the company's Company Announcement no 34/2009 released earlier
today it was stated that Novo Nordisk A/S (NYSE: NVO) and its
wholly-owned affiliates as per 22 June 2009 owned 32,741,741 of its
own B shares of DKK 1, corresponding to a total nominal value of DKK
32,741,741 or 5.2% of the total share capital.
Following the cancellation of nominally DKK 14,000,000 (14,000,000
shares) of the company's own B shares and pursuant to Section 28 and
29 of the Danish Securities Trading Act, it is hereby announced that
Novo Nordisk A/S and its wholly-owned affiliates now own 18,741,741
of its own B shares. This corresponds to a total nominal value of DKK
18,741,741 B shares or 3.0 % of the total share capital, meaning that
Novo Nordisk A/S no longer holds more than 5% of the total share
capital.
The reduction in the share capital will not affect Novo Nordisk's
share repurchase programme which will continue as previously
announced.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 27,900
employees in 81 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
Further information:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
krop@novonordisk.com
In North America: In North America:
Sean Clements Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com hrmm@novonordisk.com
Company Announcement no 35 / 2009
